Status:
NOT_YET_RECRUITING
Efficacy And Safety Of Illumination Dose Reduction In Red Light Photodynamic Therapy For Actinic Keratoses
Lead Sponsor:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Conditions:
Actinic Keratoses
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to compare the tolerance and efficacy of conventional photodynamic therapy (PDT) with red light versus PDT with red light at half dose of illumination, as well as th...
Detailed Description
The goal of the clinical trial is to compare efficacy and tolerance of photodynamic therapy (PDT) with red light at half dose illumination protocol with conventional PDT for the treatment of grade I a...
Eligibility Criteria
Inclusion
- Patient with grade I and II actinic keratoses (AK) of Olsen on the scalp requiring field cancerization treatment.
- ≥ 18 years old.
- More than 5 AK per field of cancerization to be treated.
- More than 6 months since the last field treatment for AK performed.
- No AK in clinical grade III progression of Olsen or showing signs suggestive of being invasive squamous cell carcinoma.
Exclusion
- Patients with photodermatoses.
- Patients sensitive to methyl-aminolevulinate.
- Patients with disabilities or unable to provide informed consent.
- Patients who do not tolerate or do not wish to be treated with PDT.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06545396
Start Date
August 1 2024
End Date
March 1 2025
Last Update
August 9 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.